MNPR NASDAQ
Monopar Therapeutics Inc.
1W: +2.8%
1M: +17.6%
3M: +13.1%
YTD: -5.0%
1Y: +69.9%
3Y: +1371.4%
5Y: +145.3%
$63.12
+0.44 (+0.70%)
Weekly Expected Move ±9.6%
$48
$54
$59
$65
$71
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (13)
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of “Buy” from Brokerages
Q1 EPS Estimate for Monopar Therapeutics Boosted by Analyst
HC Wainwright Issues Pessimistic Estimate for MNPR Earnings
Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of “Buy” from Analysts
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC